You are viewing: Japan AI in Precision Medicine Market analysis

The Japan AI in Precision Medicine Market was valued at $3.64 Million in 2024 and projected to reach to $13.83 Million by 2029, representing a compound annual growth rate of 19.4%. Japan's AI in Precision Medicine market is poised for significant expansion as healthcare institutions prioritize diagnostic accuracy and personalized treatment strategies.

Japan AI in Precision Medicine Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan AI in Precision Medicine Market Trends and Insights

  • Japan's healthcare sector is increasingly adopting artificial intelligence technologies to enhance diagnostic accuracy, treatment personalization, and patient outcomes across oncology, cardiology, and genomics applications.
  • The nation's advanced technological infrastructure, aging population, and strong government support for digital health initiatives position Japan as a key growth market in the Asia Pacific region. Driven by Japan's commitment to precision medicine innovation and rising healthcare expenditure, the market is expected to grow at a compound annual growth rate of 19.4% through 2029.
  • Japan's pharmaceutical and medical device companies are investing heavily in AI-powered diagnostic tools and treatment optimization platforms.
  • The convergence of Japan's expertise in robotics and automation with precision medicine applications creates significant opportunities for market expansion and clinical implementation across Japanese healthcare institutions..

Key Market Statistics

  • CAGR (2024-2029) 19.4% CAGR
  • Market Size, 2024 ~USD 3.64 Million
  • Forecast, 2029 ~USD 13.83 Million
  • Country Japan

Japan AI in Precision Medicine Market Overview

Market Valuation Growth :

Japan's AI in Precision Medicine market is valued at $3.64 million in 2024, with a projected CAGR of 19.4%, reaching $13.83 million by 2029, demonstrating strong domestic adoption momentum.

Clinical Application Expansion :

Japanese healthcare providers are increasingly deploying AI solutions across oncology, cardiology, and genomics, leveraging advanced diagnostic capabilities to improve treatment personalization and patient outcomes.

Healthcare Infrastructure Advantage :

Japan's sophisticated healthcare system, combined with aging population demographics and high digital adoption rates, creates ideal conditions for precision medicine AI integration and innovation.

Regulatory Support & Innovation :

Japan's regulatory framework and government initiatives supporting digital health transformation are accelerating AI implementation in precision medicine, positioning the nation as a regional innovation leader.

Japan AI in Precision Medicine Market Dynamics

  • The nation's aging population and prevalence of chronic diseases drive demand for advanced AI-powered solutions that enhance clinical decision-making and patient stratification.
  • Japanese pharmaceutical companies and medical device manufacturers are increasingly investing in AI capabilities to develop precision medicine applications tailored to genetic and phenotypic patient profiles. Government support for digital health infrastructure and collaborative partnerships between technology firms and healthcare providers will further accelerate market growth.
  • With a CAGR of 19.4% through 2029, Japan's precision medicine AI market reflects strong institutional commitment to modernizing healthcare delivery and improving therapeutic outcomes across multiple disease areas..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Analytical And Scientific Instrumentation

    Top Technologies
    • Environmental Testing
    • Gas Chromatography
    • Polymerase Chain Reaction (PCR)
    • Automated Liquid Handling Systems
    • Flow Cytometry
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Shimadzu Corporation
    • Merck KGaA

      Healthcare Analytics

      Top Technologies
      • Machine Learning
      • Natural Language Processing (NLP)
      • Blood Pressure Monitors
      • Computed Tomography (CT)
      • Magnetic Resonance Imaging (MRI)
      Top Companies
      • Oracle Corporation
      • PHILIPS HEALTHCARE
      • Siemens healthineers
      • Zensar Technologies Limited
      • EPIC SYSTEMS CORPORATION

        Key Takeaways

        • Japan's AI in Precision Medicine market is valued at $3.64 million in 2024 and will reach $13.83 million by 2029, representing a 19.4% CAGR.
        • Japan's aging population and advanced healthcare infrastructure drive strong demand for AI-enabled diagnostic and treatment personalization solutions.
        • Japan's pharmaceutical and medical device sectors are leading investments in AI-powered precision medicine platforms and clinical applications.
        • Japan's government support for digital health and integration with robotics expertise position the nation as a regional innovation leader in precision medicine.

        AI in Precision Medicine Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment IMAGE ANALYSIS (Tool)
        Forecast Period 2024-2029
        Growth Rate CAGR of 30.7% from 2024 to 2029
        Largest Segment SOFTWARE (Component)
        Market Size Base Year (Billions) ~USD 0.79 (2024)
        Revenue Forecast (Billions) ~USD 3.92 (2029)
        Segments Covered Application, Type, Therapeutic Area, Component, Tool, Deployment, End User, Deployment 2022-2030

        Japan AI in Precision Medicine Market Report Segmentation

        8 segment dimensions are covered across the global market.

        By Application

        • Clinical Development
        • De Novo Drug Design
        • Diagnostic & Screening
        • Diagnostics & Screening
        • Drug Discovery
        • Drug Discovery & Development
        • Drug Optimization
        • Drug Repurposing
        • Safety
        • Therapeutics
        • Understanding Diseases

        By Type

        • Deep Learning
        • Disease Diagnosis
        • Disease Progression, Staging & Prognosis
        • Disease Screening
        • Other Machine Learning Types
        • Post Treatment Surveillance & Follow-Up
        • Reinforcement Learning
        • Risk Assessment & Patient Stratification
        • Supervised Learning
        • Therapy Monitoring
        • Therapy Selection & Planning
        • Unsupervised Learning

        By Therapeutic Area

        • Cardiology
        • Hematology
        • Infectious Diseases
        • Neurology
        • Oncology
        • Other Therapeutic Area
        • Other Therapeutic Areas
        • Rare Disease
        • Rare Diseases

        By Component

        • Services
        • Software

        By Tool

        • Computer Vision
        • Context Aware Processing
        • Context-Aware Processing
        • Context-Aware Processing & Computing
        • Image Analysis
        • Machine Learning
        • Natural Language Processing
        • Nlp
        • Other Tools

        By Deployment

        • Cloud-Based
        • Cloud-Based Model
        • Hybrid
        • Hybrid Model
        • On-Premise
        • On-Premise Model

        By End User

        • Healthcare Providers
        • Medical Device/Equipment Companies
        • Other End Users
        • Pharmaceutical & Biotechnology Companies
        • Research Centers, Academic Institutes & Government Organizations
        • Research Centers, Academic Institutes, & Government Organizations

        By Deployment 2022-2030

        • Cloud Based
        • Cloud-Based
        • Hybrid
        • On-Premise

        JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030

        Segment202220232024202520262027202820292030CAGR (%)
        HEALTHCARE PROVIDERS11.6314.8919.0724.4131.2339.9451.0665.2583.3427.9
        MEDICAL DEVICE/EQUIPMENT COMPANIES6.658.4710.7913.7417.4922.2528.335.9845.7327.2
        OTHER END USERS2.573.254.15.166.518.210.3313.0116.3826
        PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES9.2811.6114.5418.1922.7528.4435.5344.3955.4325
        RESEARCH CENTERS, ACADEMIC INSTITUTES, & GOVERNMENT ORGANIZATIONS6.067.539.3511.614.3917.8422.1227.4133.9424
        TOTAL36.1845.7657.8473.1192.37116.68147.35186.03234.8126.3

        Target Audience

        • Healthcare Technology Investors : Investment firms and venture capitalists need Japan-specific market data to evaluate funding opportunities in AI precision medicine startups and assess portfolio company growth potential in this expanding market.
        • Pharmaceutical & Biotech Companies : Drug developers and biotech firms require detailed market intelligence on Japan's precision medicine AI adoption to inform R&D strategies, clinical trial design, and personalized medicine product development.
        • Medical Device Manufacturers : Device companies need Japan market insights to develop AI-integrated diagnostic and monitoring solutions aligned with local healthcare needs, regulatory requirements, and reimbursement frameworks.
        • Healthcare IT & Software Providers : Health IT vendors and software developers require Japan-specific market analysis to tailor AI precision medicine platforms, EHR integrations, and clinical decision support systems for Japanese healthcare institutions.
        • Hospital & Clinical Networks : Japanese healthcare providers and hospital systems need market data to benchmark AI adoption, identify best practices, evaluate vendor solutions, and plan precision medicine implementation strategies.

        Reasons to Buy this Report

        • Market Size & Growth Validation : Obtain precise valuation data for Japan's AI precision medicine market with verified CAGR of 19.4%, enabling accurate financial forecasting and investment decision-making for the 2024-2029 period.
        • Competitive Landscape Intelligence : Understand Japan-specific market dynamics, key players, and competitive positioning within precision medicine AI, allowing strategic planning for market entry or expansion in this high-growth segment.
        • Clinical Application Insights : Access detailed analysis of AI adoption across Japan's priority therapeutic areas—oncology, cardiology, and genomics—to identify the most promising opportunities for product development and partnerships.
        • Regulatory & Reimbursement Guidance : Gain Japan-specific insights into regulatory pathways, healthcare reimbursement models, and government initiatives supporting AI precision medicine adoption to navigate market entry effectively.
        • Strategic Partnership Opportunities : Identify collaboration potential with Japanese healthcare institutions, pharmaceutical companies, and technology providers to accelerate market penetration and establish sustainable competitive advantages.

        Frequently asked questions

        What is the current market size of AI in Precision Medicine in Japan?

        Japan's AI in Precision Medicine market was valued at $3.64 million in 2024 and is projected to grow to $13.83 million by 2029.

        What is the expected growth rate for Japan's AI in Precision Medicine market?

        Japan's AI in Precision Medicine market is expected to grow at a compound annual growth rate (CAGR) of 19.4% from 2024 to 2029.

        What factors are driving growth in Japan's AI in Precision Medicine market?

        Key drivers include Japan's aging population, advanced healthcare infrastructure, government digital health initiatives, and significant investments by pharmaceutical and medical device companies in AI-powered solutions.

        Which medical specialties are adopting AI in Precision Medicine in Japan?

        Japan's healthcare institutions are implementing AI in Precision Medicine across oncology, cardiology, genomics, and other therapeutic areas to improve diagnostic accuracy and treatment personalization.

        How does Japan's market compare to the global AI in Precision Medicine market?

        While the global market grows at 30.7% CAGR, Japan's market grows at 19.4% CAGR, reflecting Japan's mature healthcare system and more measured adoption pace compared to emerging markets.

        RESEARCH METHODOLOGY

        The study involved significant activities to estimate the current size of the AI in precision medicine market. Exhaustive secondary research was done to collect information on the AI in precision medicine market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in precision medicine market.

        Secondary Research

        This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in precision medicine solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

        Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in precision medicine vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

        Primary Research

        In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in precision medicine market.

        After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in precision medicine solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

        In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

        Breakdown of Primary Participants:

        AI in Precision Medicine Market

        Note 1: Others include sales managers, marketing managers, and product managers.

        Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

        To know about the assumptions considered for the study, download the pdf brochure

        Market Size Estimation

        Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in precision medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

        • The key players in the industry and markets have been identified through extensive secondary research.
        • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
        • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
        AI in Precision Medicine Market

        Data Triangulation

        After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

        Market Definition

        The AI in precision medicine market utilises AI technologies such as machine learning and natural language processing to analyse complicated biological and clinical data in order to provide possibly personalised healthcare solutions. It promotes applications such as drug discovery, diagnostics, predictive analytics, and tailored treatment plans by integrating genomics, proteomics, and real-world data using AI capabilities with the goal of improving patient outcomes and accelerating innovation benefits for stakeholders ranging from pharmaceutical companies and healthcare providers to researchers.

        Stakeholders

        • Transfection products manufacturing companies
        • Pharmaceutical & Biopharmaceutical Companies
        • Chemical Companies
        • Biopharmaceutical Companies
        • Contract Research Organizations (CROs)
        • Contract Development and Manufacturing Organizations (CDMOs)
        • Research Institutes and Universities 
        • Venture Capitalists & Investors
        • Government Associations

        Report Objectives

        • To define, describe, and forecast the AI in precision medicine market based on application, therapeutic area, component, tools, deployment, end user, and region.
        • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
        • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
        • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
        • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
        • To profile the key players and comprehensively analyze their market sizes and core competencies.
        • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally.

        Get the Full AI in Precision Medicine Market Report

        Full forecast, segment splits, and company analysis for all AI in Precision Medicine Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status